Meridian Bioscience Stock

Meridian Bioscience ROA

The Return on Assets (ROA) of Meridian Bioscience (VIVO) as of Sep 11, 2026 is 9.17 %. In the previous year, Return on Assets (ROA) was 15.88 % — a change of -42.26% (lower).

ROA

9.17 %

YoY

-42.26%

Last updated:

In 2026, Meridian Bioscience's return on assets (ROA) was 9.17 %, a -42.26% increase from the 15.88 % ROA in the previous year.

The Meridian Bioscience ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2015
19.37 USD
Jan 1, 2016
12.78 USD
Jan 1, 2017
8.65 USD
Jan 1, 2018
9.47 USD
Jan 1, 2019
7.50 USD
Jan 1, 2020
11.40 USD
Jan 1, 2021
15.88 USD
Jan 1, 2022
9.17 USD
The Meridian Bioscience ROA history
YEARROAYoY
9.17 %-42.26%
15.88 %+39.29%
11.40 %+52.06%
7.50 %-20.82%
9.47 %+9.48%
8.65 %-32.33%
12.78 %-34.02%
19.37 %-1.27%
19.62 %—
Access this data via the Eulerpool API
Get Free API Key

Meridian Bioscience Stock analysis

What does Meridian Bioscience do? Meridian Bioscience Inc. is a global company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. The company was founded in 1976 by William J. Motto and initially focused on the development of enzyme immunoassays (EIA). Over the years, the company has grown and diversified its product offerings, becoming a leading provider of diagnostic test kits for acute and chronic medical conditions, infectious diseases, gastrointestinal infections, and virology. The company's success is attributed to its diverse range of test kits in various medical areas, including immunology, infectious diseases, sexually transmitted diseases, gastroenterology, and virology. Additionally, Meridian Bioscience Inc. stays up-to-date with the latest technological advancements in biotechnology to ensure the fast and effective performance of its tests. The company operates globally, collaborating with universities, research institutions, government agencies, and distributors to ensure the worldwide distribution and marketing of its products. In summary, Meridian Bioscience Inc. is an innovative company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. Its wide range of products, including immunology products, infectious disease diagnostics, sexually transmitted disease test kits, gastroenterology, virology, and molecular diagnostics, coupled with advanced technologies, provides fast, accurate, and reliable diagnostic support. Meridian Bioscience is one of the most popular companies on Eulerpool.

ROA Details

Understanding Meridian Bioscience's Return on Assets (ROA)

Meridian Bioscience's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Meridian Bioscience's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Meridian Bioscience's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Meridian Bioscience’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Meridian Bioscience stock

Return on Assets (ROA) of Meridian Bioscience is 9.17 % in 2026.

Return on Assets (ROA) of Meridian Bioscience changed from 15.88 % to 9.17 %, representing a -42.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Meridian Bioscience since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Meridian Bioscience with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API
Get Free API Key

Profitability — Meridian Bioscience

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Meridian Bioscience